Announcement PDF ONCOSIL MEDICAL LIMITED ABN 89 113 824 141 ASX | OSL Level 5, 7 Eden Park Drive, Macquarie Park, NSW 2113 AUSTRALIA TELEPHONE +61 2 8935 9629 WEB www.oncosil.com 1 ASX Announcement 13 October 2026 OncoSil Medical Participates in Official Launch of PALACROS European Research Programme in Amsterdam Key points • The PALACROS European research programme has officially launched in Amsterdam, bringing together leading European hospitals, researchers and industry partners to advance treatment options for patients with locally advanced pancreatic cancer (LAPC). • OncoSil Medical Europe GmbH is a consortium partner through its participation in the PULSE Phase II clinical study, which will investigate repeat OncoSil™ treatment in 120 patients across five European centres. • The official kick-off meeting marks an important milestone in the commencement of coordinated activities across the PALACROS consortium. • The collaboration aims to improve access to multidisciplinary pancreatic cancer care and support the development of innovative treatment strategies across Europe. • OncoSil™ device treatments provided in-kind as part of the trial, with no other study related-costs applicable, resulting in significant cost savings (est. $9M) versus an OncoSil Medical sponsored study. Sydney, Australia – 13 October 2026: OncoSil Medical Limited (ASX: OSL) (“OncoSil Medical” or “the Company”), a medical device company focused on localised treatments for patients with unresectable locally advanced pancreatic cancer (LAPC) and distal cholangiocarcinoma (dCCA), is pleased to announce its participation in the official launch of the PALACROS European research programme, held in Amsterdam, the Netherlands. The launch brought together leading European clinical institutions, researchers, patient organisations and industry partners to formally commence the collaborative initiative aimed at improving treatment outcomes and expanding access to specialised multidisciplinary care for patients with locally advanced pancreatic cancer. OncoSil Medical, through its European subsidiary OncoSil Medical Europe GmbH, is participating in the consortium through the PULSE Phase II clinical study, which will investigate repeat treatment with the OncoSil™ device in 120 patients across five European centres. The official kick-off meeting provided an opportunity for consortium partners to align on the programme's objectives, research priorities and collaborative activities as PALACROS moves into its implementation phase. ONCOSIL MEDICAL LIMITED ABN 89 113 824 141 ASX | OSL Level 5, 7 Eden Park Drive, Macquarie Park, NSW 2113 AUSTRALIA TELEPHONE +61 2 8935 9629 WEB www.oncosil.com 2 Nigel Lange, CEO & Managing Director of OncoSil Medical, said: “The official launch of PALACROS in Amsterdam represents an important milestone in bringing together leading European institutions to advance pancreatic cancer research and treatment. We are pleased to be part of this collaborative initiative through the PULSE Phase II study and to contribute to a programme focused on improving treatment options for patients with locally advanced pancreatic cancer. We look forward to working closely with our consortium partners as PALACROS progresses.” Advancing European Collaboration in Pancreatic Cancer Care PALACROS is a European research initiative supported by the Horizon Europe programme and the EU Mission on Cancer, bringing together multidisciplinary expertise to investigate innovative treatment approaches and improve care pathways for patients with locally advanced pancreatic cancer. The programme seeks to strengthen collaboration between specialist treatment centres, support the generation of clinical evidence and address disparities in access to advanced pancreatic cancer care across Europe. For OncoSil Medical, participation in the consortium provides an opportunity to engage with leading European pancreatic cancer specialists and contribute to a coordinated research effort focused on improving patient outcomes. Under the study agreement, OncoSil Medical will provide OncoSil™ devices in-kind, with no additional study- related costs to be incurred by the Company. This enables the generation of valuable clinical data in LAPC without the significant site, monitoring, regulatory, data management and operational expenses typically associated with a company-sponsored trial of similar scale and duration. As a result, the arrangement is expected to deliver an estimated cost saving of approximately $9 million compared with conducting an equivalent OncoSil Medical-sponsored study, while allowing the Company to benefit from the clinical evidence generated. The in-kind structure therefore represents a highly capital- efficient approach to expanding the clinical evidence base for the OncoSil™ device in LAPC, with the trial sponsor bearing the associated study costs rather than the Company. Key study details include: • Study design: Phase II, multi-centre, randomised (1:1) • Patients: 120 participants across five European centres • Patient population: Patients with unresectable, non-progressive LAPC following at least four months of induction chemotherapy • Treatment arms: o Single OncoSil™ device implantation; or o Repeat OncoSil™ device implantation every three months until disease progression ONCOSIL MEDICAL LIMITED ABN 89 113 824 141 ASX | OSL Level 5, 7 Eden Park Drive, Macquarie Park, NSW 2113 AUSTRALIA TELEPHONE +61 2 8935 9629 WEB www.oncosil.com 3 • Primary endpoint: Nine-month local progression-free survival • Secondary endpoints: Overall progression-free survival, overall survival, safety and tolerability, quality of life, pain, opioid use, conversion to surgical resection, and biomarker assessment. • The study will also include a health economic assessment evaluating the cost-effectiveness and budget impact of repeat versus single OncoSil™ device implantation. The PULSE Trial builds on earlier prospective clinical studies, including TRIPP-FFX, PANCOSIL and PANCO, and aims to generate multicentre evidence pertaining to the role of repeat OncoSil™ device treatment in improving local tumour control and potentially increasing the number of patients eligible for curative surgery. PALACROS also identifies innovative local therapies, including the OncoSil™ device, as a key component of its strategy to improve outcomes for patients who remain unresectable after chemotherapy. The programme seeks to generate prospective evidence on therapies that may improve local disease control and increase conversion to surgical candidates. Click here to view this announcement on Investor Hub. Authorisation & Additional Information This announcement was authorised by the Board of Directors of OncoSil Medical Limited. For further information, please contact: About OncoSil Medical OncoSil Medical (ASX) is a global medical device company focused on Interventional Oncology, with a mission to improve outcomes for people living with cancer. The company has developed OncoSil™, a single-use brachytherapy (internal radiation) device that delivers a pre-determined dose of beta radiation directly into cancerous tissue using targeted intratumoural placement of Phosphorous-32 (³²P) Microparticles. Its targeted approach enables a greater radiation dose to be delivered directly to the tumour while limiting exposure to surrounding critical organs. In the United States, OncoSil™ is indicated for the treatment of patients with distal cholangiocarcinoma (dCCA) that is both unresectable (locally advanced and/or unfit for surgery) and non-metastatic, as an adjunct to systemic therapy. In markets outside the United States where OncoSil™ has received regulatory approval, OncoSil™ is indicated for the treatment of patients with unresectable locally advanced pancreatic cancer, in addition to gemcitabine-based chemotherapy. Pancreatic cancer is the 12th most common cancer in men and the 11th most common cancer in women across the globe, with 500,000 new cases detected every year1. Since pancreatic cancer is generally diagnosed at a later stage, it has a poor prognosis for long-term survival. Distal cholangiocarcinoma (dCCA) is a rare form of bile duct cancer. It is often diagnosed at an advanced stage, when surgical treatment may no longer be possible, and is associated with a poor prognosis. OncoSil™ has received CE Marking approval, providing marketing authorisation in the European Union and the United Kingdom. OncoSil™ has also received approval from the U.S. Food and Drug Administration (FDA) under a Humanitarian Device Exemption (HDE) for the treatment of patients with unresectable, non-metastatic distal cholangiocarcinoma (dCCA), as an adjunct to systemic therapy. OncoSil™ has been designated as a Breakthrough Device in Europe and the United States. It is currently approved for sale in 30+ countries, including the European Union, United Kingdom, United States, Australia, Saudi Arabia, Türkiye and Israel, with commercial Mr. Nigel Lange CEO & Managing Director E: nigel.lange@oncosil.com T: +49 160 9642 4981 Mr. Tim Luscombe & Ms. Nova Taylor Joint Company Secretaries E: tim.luscombe@bio101.com & nova.taylor@bio101.com T: +61 429 707 079 & +61 414 877 703 ONCOSIL MEDICAL LIMITED ABN 89 113 824 141 ASX | OSL Level 5, 7 Eden Park Drive, Macquarie Park, NSW 2113 AUSTRALIA TELEPHONE +61 2 8935 9629 WEB www.oncosil.com 4 treatments using the device already undertaken in Spain, Italy, Austria, Germany, Greece, Türkiye, Portugal, Israel and the UK. To learn more, please visit: www.oncosil.com/ 1 https://gco.iarc.fr/en